MiMedx Group Inc. reported net sales of $113.7 million for the third quarter ended September 30, 2025, representing a 35.3% increase compared to $84.1 million in the same period of 2024. Net sales of wound products reached $77.0 million, up 40% from the prior year, while sales of surgical products were $37.0 million, an increase of 26%. Gross profit for the quarter was $95.0 million, a 38.2% rise from $68.7 million in the third quarter of 2024. Selling, general and administrative expenses totaled $69.0 million, up 28.9%. Research and development expenses increased by 26.9% to $3.7 million. Net income from continuing operations for the quarter was $16.7 million, an increase of 112.6% from $7.9 million in the prior year period. GAAP fully diluted earnings per share for the third quarter of 2025 were $0.11, compared to $0.05 in the same period last year. The company's cash balance increased by $23 million to $142 million. For the nine months ended September 30, 2025, MiMedx reported net sales of $300.5 million, up 17.4% from $256.0 million for the same period in 2024. Net income from continuing operations for the nine-month period was $33.4 million, compared to $34.6 million a year earlier.